Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections; lactose monohydrate - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; treatment of advanced colorectal cancer.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxaliplatin, quantity: 100 mg - injection, powder for - excipient ingredients: lactose monohydrate - oxaliplatin is indicated for adjuvant treatment of stage iii (duke's c) colon cancer, in combination with a fluoropyrimidine agent,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - oxaliplatin, quantity: 200 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke's c) colon cancer, in combination with a fluoropyrimidine agent,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke's c) colon cancer, in combination with a fluoropyrimidine agent,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxaliplatin, quantity: 200 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke's c) colon cancer, in combination with a fluoropyrimidine agent,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke's c) colon cancer, in combination with a fluoropyrimidine agent,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer

Kanada - inglise - Health Canada

actavis pharma company - oxaliplatin - powder for solution - 50mg - oxaliplatin 50mg - antineoplastic agents

Singapur - inglise - HSA (Health Sciences Authority)

pfizer private limited - oxaliplatin - infusion, solution concentrate - 50mg - oxaliplatin 50mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - oxaliplatin - powder for solution for infusion - 50mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - oxaliplatin - powder for solution for infusion - 50mg